AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Geron Appoints Harout Semerjian as President and CEO
ByAinvest
Saturday, Aug 9, 2025 2:21 am ET1min read
Geron Corporation has appointed Harout Semerjian as its new President and CEO, effective tomorrow. Semerjian brings over 30 years of experience in hematology and oncology from his tenure at Novartis, Ipsen, and GlycoMimetics. He succeeds Dawn Carter Bir, who will continue to support the company as a member of its Board of Directors. Geron is focusing on its Phase 3 trial for relapsed/refractory myelofibrosis and aims to expand the reach and impact of its flagship product, RYTELO.
Geron Corporation (GERN) has appointed Harout Semerjian as its new President and Chief Executive Officer (CEO), effective August 7, 2025. Semerjian, a seasoned biopharmaceutical executive with over 30 years of experience in hematology and oncology, succeeds Dawn Carter Bir, who will continue to support the company as a member of its Board of Directors [1][2][3].Semerjian brings a wealth of experience from his tenure at Novartis, Ipsen, and GlycoMimetics. At Novartis, he played a key role in the global launch and commercial strategy of Gleevec® and KISQALI®. At Ipsen, he served as Executive Vice President and Chief Commercial Officer, overseeing global commercial strategy across multiple therapeutic areas. His most recent role was as CEO of GlycoMimetics, where he guided the company through its acquisition by Gilead Sciences [1][2][3].
Geron is focusing on its Phase 3 trial for relapsed/refractory myelofibrosis and aims to expand the reach and impact of its flagship product, RYTELO. RYTELO is a first-in-class telomerase inhibitor with the potential to reshape treatment paradigms for patients with myelodysplastic syndromes. Under Semerjian's leadership, Geron has expanded physician education and payer engagement, leading to rapid uptake of RYTELO with over 1,000 active ordering accounts within the first quarters of commercialization [1][2][3].
Semerjian's appointment comes at a pivotal moment for Geron. The company is working to increase awareness and accessibility of RYTELO and to advance its late-stage pipeline, including the completion of the pivotal Phase 3 IMpactMF trial in relapsed/refractory myelofibrosis [1][2][3].
References:
[1] https://oncodaily.com/career/harout-semerjian
[2] https://www.nasdaq.com/articles/geron-appoints-harout-semerjian-ceo
[3] https://www.biospace.com/press-releases/geron-appoints-harout-semerjian-as-president-and-chief-executive-officer
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet